Abstract 3864
Background
Role of Tg levels as a biomarker in RAI-R DTC during MKI is unclear. Falling levels of Tg after starting MKI treatment has been previously reported, with a higher reduction in patients who achieve response. However, transient Tg oscillations are a common phenomenon during therapy without a clear correlation with progressive disease (PD). In the present study, we analyze the correlation between Tg oscillations and progression-free survival (PFS) in patients with RAI-R DTC during MKI treatment.
Methods
Thirty-seven consecutive patients were reviewed. Inclusion criteria were: pathology confirmed RAI-R DTC, age >18 years, MKI treatment in the first or second line and serial Tg determinations along with the follow-up. Variations in Tg levels during MKI treatment were evaluated. As exploratory hypothesis, we considered the “Tg elevation non-PD related”, defined as a significant elevation of Tg higher than 50% compared with previous measure, not related with PD by RECIST criteria, followed by a Tg reduction in a subsequent determination, in patients with an initial Tg reduction after starting MKI treatment.
Results
33 patients were included in the final analysis. Most MKI treatments were Sorafenib (44%), Lenvatinib (27%), Vandetanib (10%) and Axitinib (8%). Median duration of treatment was 15.5 months, and median PFS 20.2 months. Patients with any Tg levels reduction compared with baseline along MKI treatment showed a better PFS (23.5 vs. 3.6 months, p < 0.001). A Tg reduction >50% from baseline on the first month after starting MKI also had a benefit in PFS (27.7 vs. 14.2, p 0.02). 20.6% of cases had the nadir of Tg response beyond the first month of treatment. 34.4% of cases presented Tg elevation non-PD related along with follow-up (median number of elevations per patient: 2), with a better PFS compared with patients with other Tg oscillation patterns (29.9 vs. 15.5 months, p0.008).
Conclusions
Tg elevation non-PD related was associated with a better PFS compared with patients with other Tg variation patterns. Treatment with MKIs should not be stopped or changed based on Tg variations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Hernando Cubero: Speaker Bureau / Expert testimony: Eisai, Ipsen, Roche, Angelini Pharma; Travel / Accommodation / Expenses: Ipsen, Novartis, AAA, Roche, AstraZeneca, Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
3931 - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract
5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.
Presenter: Philippe Ruszniewski
Session: Poster Display session 2
Resources:
Abstract
1234 - Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in Gastroenteropancreatic neuroendocrine carcinoma
Presenter: Jia Zhang Xing
Session: Poster Display session 2
Resources:
Abstract
1517 - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis
Presenter: Zhiyao Fan
Session: Poster Display session 2
Resources:
Abstract
2145 - Investigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification
Presenter: Takahiro Yokose
Session: Poster Display session 2
Resources:
Abstract
3134 - Treatment with somatostatin analogues after radiopeptide therapy
Presenter: Daria Handkiewicz Junak
Session: Poster Display session 2
Resources:
Abstract
2191 - Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.
Presenter: Rahul Ladwa
Session: Poster Display session 2
Resources:
Abstract
3581 - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients
Presenter: Carine Mauro
Session: Poster Display session 2
Resources:
Abstract
5374 - Establishment of Prognostic Nomogram Based on the Metastatic Lymph Nodes Ratio for Patients with Gastric Neuroendocrine Tumour
Presenter: yaobin lin
Session: Poster Display session 2
Resources:
Abstract